At BCRC-WA, our dedicated Breast Clinical Trials Unit (BCTU) performs many clinical trials including those designed to evaluate new treatments versus current (approved) treatments, evaluate approved treatments in new settings, evaluate ways of reducing side effects of treatment, expand the understanding of the biological behavior of breast cancer and investigate the social and emotional impact of breast cancer on patients and their families.
Early Breast Cancer
ELEGANT
Status:
Active – Recruiting
Title:
The ELEGANT Study: A global, multicenter, randomized, open-label phase 3 study that will evaluate the efficacy of elacestrant relative to standard-of-care endocrine therapy (SOC ET) in patients with ER+/HER2- node positive, early breast cancer with high risk of recurrence.
Trial ID
Type
Adjuvant
Cancer Type
ER+/HER2- node positive, early breast cancer with high risk of recurrence
For full inclusion / exclusion criteria you can visit the Australian Cancer Clinical Trials Registry
Metastatic Breast Cancer
OPERA-01
Status:
Active – Recruiting
Title:
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Trial ID
Type
2nd or 3rd line
Cancer Type
ER positive, HER2 negative
For full inclusion / exclusion criteria you can visit the Australian Cancer Clinical Trials Registry
OPERA-02
Status:
Active – Recruiting
Title:
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Trial ID
Type
1st line
Cancer Type
ER+, HER2- advanced breast cancer
For full inclusion / exclusion criteria you can visit the Australian Cancer Clinical Trials Registry
VIKTORIA-2
Status:
Active – Recruiting
Title:
A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
Trial ID
Type
1st Line
Cancer Type
HR Positive, HER2 Negative
For full inclusion / exclusion criteria you can visit the Australian Cancer Clinical Trials Registry
Referrals
If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit our referrals page for referral information.
For more information on clinical trials, get in contact with our Breast Clinical Trial Unit:
Breast Clinical Trials Unit (BCTU)
Business hours, Mon to Friday between 9am – 5pm
Email: BCTU@bcrc-wa.com.au
Phone: (08) 6500 5575
This page was updated in March 2024
